Metaverse Struggles to Achieve Mass Adoption as Funding Continues to Fall

 

The Sims may be one of the best-selling video game franchises of all-time, but companies are struggling to make that digital world a reality.

Funding has been on a steady decline over the past year for the metaverse as it has struggled to achieve mass adoption across a wide user base. This trend has potential users and investors alike wondering if this digital world will ever be the version, we had hoped it would be.

However, some AAA deals have still shown promise with companies like LootMogul, Scandit and others still securing multi-million-dollar deals despite the funding downturn.

Mouaadh ‘Miso’ Bellaour, 3D artist and CEO of Monoware Studios, believes we’ll need a culture shift towards a digital-first world before mass adoption can truly take off.

“In order for the Metaverse to see further adoption, the Metaverse has to reconcile with the daily lives of its potential users. It’s difficult to say that there’s a definitive tipping point in terms of where 3D technology needs to be. It is easy to say, however, that some scope of the Metaverse, the broadest definition of it Is already a part of our lives.

It’s the digital world that we interact with daily, and like the foundation of the internet, an open protocol is the best solution to innovating the metaverse to greater adoption, and it has to be a set of tools that anyone can use and make their own without restriction.”

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More